Arthritis & rheumatology (Hoboken, N.J.) · 2026
Outcomes of Tapering Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: A Multicenter Randomized Non-Inferiority Trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Park Dong-Jin, Choi Sung-Eun, Kang Ji-Hyoun, Choe Jung-Yoon, Lee Hye-Soon, Bang So-Young, Cheon Yun-Hong, Lee Sang-Il, Kim Mingyo, Sung Yoon-Kyoung, Cho Soo-Kyung, Jung Jae Hyun, Chang Sung Hae, Lee Sung Won, Lee Yeon-Ah, Lee Seung-Geun, Kim Hyun-Sook, Kwok Seung-Ki, Shim Seung-Cheol, Lee Shin-Seok
Аннотация
OBJECTIVE: Evidence supporting tapering of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) patients with sustained low disease activity (LDA) remains limited. We evaluated the efficacy and safety of a structured b/tsDMARD tapering strategy in patients with RA who had achieved sustained LDA.
METHODS: In this 24-week, multicenter, randomized, open-label, non-inferiority trial, patients with RA receiving stable-dose b/tsDMARDs and maintaining DAS28-ESR-defined LDA for at least 6 months were randomized to either stepwise dose tapering or dose continuation. The primary endpoint was maintenance of DAS28-ESR LDA at week 24. The non-inferiority margin was prespecified as -10%. Secondary endpoints included disease activity measures, remission rates, patient-reported outcomes, quality of life, and adverse events.
RESULTS: A total of 348 patients were randomized to the continuation group (n=177) or tapering group (n=171). In the per-protocol population, LDA was maintained in 89.6% and 88.2% of patients, respectively, with a risk difference of -1.43% (95% CI -8.09 to 5.23), meeting the prespecified criterion for non-inferiority. Similar findings were observed in the full analysis set. Most patients experiencing disease worsening regained low disease activity after protocol-guided treatment re-escalation during follow-up without permanent treatment discontinuation. Most secondary outcomes were comparable between groups, although some disease activity measures favored continuation, including DAS28-CRP at week 12 and DAS28-ESR and SDAI at week 24. Adverse events were uncommon in both groups.
CONCLUSION: In RA patients with sustained LDA, structured b/tsDMARD tapering was non-inferior to treatment continuation for maintaining disease control over 24 weeks.
METHODS: In this 24-week, multicenter, randomized, open-label, non-inferiority trial, patients with RA receiving stable-dose b/tsDMARDs and maintaining DAS28-ESR-defined LDA for at least 6 months were randomized to either stepwise dose tapering or dose continuation. The primary endpoint was maintenance of DAS28-ESR LDA at week 24. The non-inferiority margin was prespecified as -10%. Secondary endpoints included disease activity measures, remission rates, patient-reported outcomes, quality of life, and adverse events.
RESULTS: A total of 348 patients were randomized to the continuation group (n=177) or tapering group (n=171). In the per-protocol population, LDA was maintained in 89.6% and 88.2% of patients, respectively, with a risk difference of -1.43% (95% CI -8.09 to 5.23), meeting the prespecified criterion for non-inferiority. Similar findings were observed in the full analysis set. Most patients experiencing disease worsening regained low disease activity after protocol-guided treatment re-escalation during follow-up without permanent treatment discontinuation. Most secondary outcomes were comparable between groups, although some disease activity measures favored continuation, including DAS28-CRP at week 12 and DAS28-ESR and SDAI at week 24. Adverse events were uncommon in both groups.
CONCLUSION: In RA patients with sustained LDA, structured b/tsDMARD tapering was non-inferior to treatment continuation for maintaining disease control over 24 weeks.